Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 21, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on September 14, 2018 , the Board of Directors approved "inducement" grants to nine new employees under Rule
View HTML
Toggle Summary Arrowhead Presents New ARO-HBV Clinical Data Demonstrating HBsAg Reductions at World Gastroenterologists Summit
Data presented from the lowest two dose cohorts (100mg and 200mg ARO-HBV) Up to 4.0 log10 reduction in HBsAg observed following three doses of ARO-HBV ARO-HBV was generally well-tolerated in HBV patients PASADENA, Calif. --(BUSINESS WIRE)--Sep. 6, 2018-- Arrowhead Pharmaceuticals Inc.
View HTML
Toggle Summary Arrowhead Completes Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
PASADENA, Calif. --(BUSINESS WIRE)--Aug. 31, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has completed dosing of a Phase 1 clinical study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Present at Upcoming September 2018 Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Aug. 30, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the following upcoming events: Annual B. Riley FBR Healthcare Conference – New York , September 4, 2018 Bruce Given , M.D., Arrowhead’s chief
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2018 Third Quarter Results
- Conference Call and Webcast Today at 4:30 p.m. EDT PASADENA, Calif. --(BUSINESS WIRE)--Aug. 7, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2018 third quarter ended June 30, 2018 . The company is hosting a conference call at 4:30 p.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Earns $10 Million Milestone Payment from Amgen
PASADENA, Calif. --(BUSINESS WIRE)--Aug. 1, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has earned a $10 million milestone payment from Amgen following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a clinical study.
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Third Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 24, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 7, 2018 , at 4:30 p.m. EDT to discuss its financial results for the fiscal 2018 third quarter ended June 30, 2018 .
View HTML
Toggle Summary Arrowhead Presents New Clinical Data on ARO-AAT at Alpha-1 National Education Conference
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 29, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today will present preclinical and initial clinical data on ARO-AAT, the company’s second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a treatment for a
View HTML
Toggle Summary Arrowhead Receives Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 27, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on Arrowhead’s application for orphan designation of its RNAi
View HTML
Toggle Summary Arrowhead Completes Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 18, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has completed enrollment of a Phase 1 clinical study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed
View HTML